Indeed, primary GBM are essentially characterized by an amplification of EGFR (epidermal growth factor receptor) (36%), a deletion of p16InK4a (p16 cyclin-dependent kinase inhibitor 4a) (31%) and a mutated PTEN (phosphatase and tensin homolog) (25%). Here, PTEN is linked to glioblastoma.